Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2022-08-01 00:00:00 ET · period of report 2022-07-28 · accession 0001209191-22-043764 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-01 | 2022-07-28 | ORMP | Rabinowitz Michael | Chief Commercial Off | A - Grant | — | +30.0K | 139.5K | +27% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-28 | A | A | 30,000 | — | 139,468 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |